Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Breast Cancer

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1636472

Tissue Expander Breast Reconstruction Outcomes following Postmastectomy Radiation Therapy in the Era of Neoadjuvant Chemotherapy

Provisionally accepted
Oscar  PadillaOscar Padilla1,2Meghan  JairamMeghan Jairam3Amanda  YenAmanda Yen4Julie  ChoiJulie Choi4Elizabeth  BussElizabeth Buss4Christine  ChinChristine Chin5Leah  KatzLeah Katz4Jeffery  AschermanJeffery Ascherman2Eileen  P ConnollyEileen P Connolly4*
  • 1Icahn School of Medicine at Mount Sinai, New York, United States
  • 2New York-Presbyterian/Columbia University Irving Medical Center, New York, United States
  • 3Brigham and Women's Hospital, Boston, United States
  • 4Columbia University Irving Medical Center, Columbia University, New York, United States
  • 5Nuvance Health, Danbury, United States

The final, formatted version of the article will be published soon.

Optimal sequencing of mastectomy, tissue expander breast reconstruction (TE-BR), chemotherapy, and post-mastectomy radiotherapy (PMRT) remains unclear. While PMRT is known to impact TE-BR outcomes, limited data exist comparing outcomes between patients who also receive neoadjuvant chemotherapy (NAC) versus adjuvant chemotherapy (AC).A retrospective review of 126 patients diagnosed with invasive breast carcinoma who underwent mastectomy, TE-BR, and PMRT between 2001 and 2017 was conducted. Patients were stratified into NAC (n=74) and AC (n=52) cohorts. Logistic regression and Kaplan-Meier analyses evaluated TE-BR failure rates, completion rates, and radiation toxicity. Multivariate Cox proportional hazard regression modeled TE-BR failure probability.TE-BR failure rates were significantly higher in the NAC group (44.6% at a median of 18.7 months) compared to the AC group (26.9% at 23.2 months, p=0.041). Moreover, NAC was associated with increased adverse events and lower TE-BR completion rates (both p=0.001). Univariate analysis identified NAC (p=0.007) and acute RT toxicity (p<0.001) as predictors of TE-BR failure. Multivariate analysis confirmed NAC (HR 2.73, p=0.003) and acute RT toxicity (HR 3.16, p<0.001) as independent risk factors. Acute RT toxicity rates were similar between NAC and AC groups (p=0.604). Completing TE expansion before PMRT in NAC patients was linked to higher failure probability (HR 2.58, p=0.023).Our study is the first to report TE-BR outcomes in women who undergo NAC versus AC in the context of PMRT. Our findings indicate inferior TE-BR outcomes following NAC when PMRT is delivered, emphasizing the importance of shared decision-making between patients and doctors about optimal surgical choice. If eligible, breast conservation or alternate BR technique should be strongly considered in the setting of NAC and future research should explore optimal reconstruction strategies.

Keywords: radiation therapy, breast cancer, oncology, post mastectomy radiation therapy, Post mastectomy radiotherapy (PMRT), Tissue expander implant breast surgery

Received: 27 May 2025; Accepted: 07 Aug 2025.

Copyright: © 2025 Padilla, Jairam, Yen, Choi, Buss, Chin, Katz, Ascherman and Connolly. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Eileen P Connolly, Columbia University Irving Medical Center, Columbia University, New York, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.